NASDAQ:FGENFibroGen Stock Price, Forecast & News

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FGEN stock has increased by 27.5% and is now trading at $45.15.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for FibroGen.

FibroGen is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for FibroGen.

FibroGen Inc (NASDAQ:FGEN) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.64) by $0.31. The biopharmaceutical company earned $42.90 million during the quarter, compared to analysts' expectations of $48.29 million. FibroGen had a negative return on equity of 57.40% and a negative net margin of 287.01%. The business's revenue for the quarter was down 77.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.26 EPS.
View FibroGen's earnings history.

5 Wall Street analysts have issued twelve-month price targets for FibroGen's shares. Their forecasts range from $40.00 to $84.00. On average, they expect FibroGen's stock price to reach $58.40 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price.
View analysts' price targets for FibroGen.

News articles about FGEN stock have trended somewhat negative recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. FibroGen earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about FibroGen.

Some companies that are related to FibroGen include Horizon Therapeutics (HZNP), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ) and Emergent Biosolutions (EBS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include First Trust Advisors LP (1.89%), Principal Financial Group Inc. (0.29%), Candriam Luxembourg S.C.A. (0.24%), New York State Common Retirement Fund (0.24%), Swiss National Bank (0.20%) and Rhenman & Partners Asset Management AB (0.16%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura.
View institutional ownership trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, UBS Group AG, Alps Advisors Inc., WINTON GROUP Ltd, Candriam Luxembourg S.C.A., Envestnet Asset Management Inc., Amalgamated Bank, and Arizona State Retirement System. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen.

FGEN stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Principal Financial Group Inc., SG Americas Securities LLC, Mutual of America Capital Management LLC, Swiss National Bank, Rafferty Asset Management LLC, Mackay Shields LLC, and Aigen Investment Management LP.
View insider buying and selling activity for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $45.15.

FibroGen has a market capitalization of $4.08 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]